Rajen Desai, MD
Ophthalmology · Freehold, NJNPI 1174788699
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $194,331 of the $311,310 with a category attached, or 62.4%. 29 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 41.9% of the total. 2025 is the largest year on record at $146,413, more than ten times the $6,083 reported in 2019. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 712 payments — averaging $437.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$130K
- AbbVie$53K
- Glaukos Corporation$48K
- Rayner Intraocular Lenses Limited$21K
- NEW World Medical,inc.$10K
- Beaver-visitec International, Inc.$10K
- plus $38K from 23 others
Across 2 payments — averaging $6500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$13K
What the payments were for
- Consulting fees$73,13523%
- Speaking & faculty fees$194,33162%
- Travel & lodging$22,3117%
- Food & beverage$18,3166%
- Education$3,1721%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 146 | $130,369 |
| AbbVie(2 entities) | 172 | $53,283 |
| Glaukos Corporation | 55 | $48,481 |
| Rayner Intraocular Lenses Limited | 17 | $21,077 |
| NEW World Medical,inc. | 27 | $10,270 |
| Beaver-visitec International, Inc. | 6 | $9,525 |
| Sight Sciences, Inc. | 34 | $9,484 |
| Alcon | 26 | $6,211 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 31 | $6,010 |
| Sun Pharmaceutical Industries Inc. | 52 | $5,140 |
| Ocular Therapeutix, Inc. | 11 | $4,073 |
| Ivantis, Inc | 4 | $2,632 |
| Iridex Corporation | 9 | $1,793 |
| Johnson & Johnson Surgical Vision, Inc. | 31 | $1,257 |
| Microsurgical Technology, Inc. | 2 | $382 |
| Novartis | 35 | $345 |
| Biotissue Holdings Inc. | 16 | $266 |
| Mallinckrodt Hospital Products Inc. | 4 | $136 |
| Kala Pharmaceuticals, Inc. | 9 | $132 |
| Eyepoint US, Inc. | 6 | $84 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $73 |
| Tarsus Pharmaceuticals, Inc. | 4 | $67 |
| Oyster Point Pharma, Inc. | 4 | $67 |
| Nova Eye, Inc. | 2 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Aerie Pharmaceuticals, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $24 |
| Amgen | 1 | $18 |
| Harrow Eye, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$64,214
- XIIDRA$64,214
- VYZULTA$43,717
- DURYSTA$42,637
- enVista MX60 IOL$36,180
- Travoprost Intraocular Implant - iDose$25,475
- RayOne EMV$16,384
- RayOne Spheric$16,384
- RayOne Aspheric$16,384
- iDose$9,939
- Ahmed Glaucoma Valve$9,208
- Kahook Dual Blade$9,208
- Hydrus Microstent$8,322
- OMNI(R) SURGICAL SYSTEM (US)$7,802
- enVista Aspire IOL$6,830
- LUMIGAN$6,122
- COMBIGAN$5,059
- IC-8 Apthera IOL$4,894
- Clearpath$4,700
- Streamline$4,700
How this compares
$311,310 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 236 | $111,676 |
| CequaCyclosporine | 58 | $62,499 |
| XiidraLifitegrast | 37 | $56,502 |
| VyzultaLatanoprostene Bunod | 101 | $38,942 |
| MieboPerfluorohexyloctane/Pf | 39 | $34,339 |
| Prednisolone Acetate | 948 | $28,476 |
| RestasisCyclosporine | 20 | $24,106 |
| MoxifloxacinMoxifloxacin Hcl | 706 | $16,067 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $11,543 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 21 | $5,246 |
| Diclofenac Sodium | 521 | $5,076 |
| Brimonidine Tartrate | 121 | $4,875 |
| Latanoprost | 344 | $4,147 |
| Methazolamide | 25 | $3,717 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 202 | $3,021 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $53,283 | $147,324286 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $130,369 | $129,783177 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $5,140 | $62,49958 claims |
| AlconSimbrinza | $6,211 | $5,24621 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $6,010 | $2,18416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Freehold
- Alain BauzaFreehold$58K
- Eric GershenbaumFreehold$23K
- Revathi NaadimuthuFreehold$12K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.